Texas’ lawsuit against Johnson & Johnson for its off-label marketing of Risperdal, which the state alleges involved fraudulent claims about the drug’s safety and effectiveness, begins today. This case promises to reveal much about the financial relationships between J&J and the academic psychiatrists who promoted the use of Risperdal to Medicaid patients.
Read more Discuss →
